Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks joboggi for your thoughts.
Thoughts on comparison, if any" between GEDi test compared to MANF for retinal degeneration?
http://www.newswise.com/articles/view/626456/?sc=dwhn
The GEDi test is offered on a CLIA-certified basis through the Ocular Genomics Institute (OGI) at Mass. Eye and Ear just lifted an embargo in the Genetics in Medicine on Nov 20, 2014.
Thanks,
Just the type work Sanford-Burham and Baynan do. It is a good fit.
However, Sanford-Burham does get involved with many clinical trials and top notch research.
Zoom,
You may or may not be aware of this.
Henry L Nordhoff is the Executive Chairman of the Board of Directors at Baynan is also on the Board of Trustees of the non-profit Sanford-Burnham Medical Research Institute in San Diego.
http://www.banyanbio.com/?page_id=22
http://www.sanfordburnham.org/talent/Pages/home.aspx
In January 2014 Sanford-Burham received a pledge of $ 275 million over 10 years.
"Our scientists will accelerate the pursuit of novel insights into the fundamental mechanisms of human biology and disease, and development of innovative, personalized therapeutic approaches past the conventional point where nonprofit institutes hand off their scientific discoveries. Existing and new partnerships with health-care organizations such as Mayo Clinic, Florida Hospital, and Sanford Health will foster two-way communication between basic and clinical researchers to inform each partner’s research and ensure that basic science is grounded in clinical reality...
Further, we will more vigorously pursue research breakthroughs into the realm of therapeutics development by leveraging our small-molecule drug discovery platform—the most advanced in the nonprofit research world. The Institute will refine drug candidates through pre-clinical validation to facilitate stronger partnerships with pharmaceutical companies such as those that currently exist with Takeda, Pfizer, and Janssen Pharmaceuticals. This more robust therapeutics-discovery engine is expected to generate future revenue by partnering with the commercial sector..."
http://beaker.sanfordburnham.org/2014/01/a-new-10-year-vision-launched-with-a-landmark-gift/
Check out the Catagories on the right of the above link.
Not all funding needs to come through the NIH.
DH
Blood-based diagnostics of traumatic brain injuries
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063529/
1Banyan Biomarkers, Inc., 12085 Research Drive, Alachua, FL 32615, USA
2University of Florida, FL, USA
*These authors contributed equally to this article.
†Author for correspondence: Email: kwang@banyanbio.com
How about direct funding coming from Sanford-Burnham. I posted yesterday about Sanford-Burnham.
...
Another unique aspect of Sanford-Burnham’s approach is its increased emphasis on diversified funding sources, including reinvested drug discovery revenue, philanthropy, and grants. In support of its long-term strategic vision, the Institute also announced that it has received a $275 million pledge payable over 10 years, the largest philanthropic commitment ever received by the Institute. This gift, which was given anonymously, will propel the Institute toward achieving its goal of raising $500 million over the next decade. ...
“http://www.newswise.com/articles/sanford-burnham-board-of-trustees-approves-new-10-year-strategic-vision?ret=/articles/list&category=business&page=1&search%5Bstatus%5D=3&search%5Bsort%5D=date+desc&search%5Bsection%5D=40&search%5Bhas_multimedia%5D=
CEO Henry Nordhoff, San Diego biotech veteran and executive chairman of Banyan Biomarkers is on the board of Stanford-Burnham
“There’s an awful lot of intellectual capital in San Diego, with the Burnham (Sanford-Burnham Medical Research Institute), I sit on that board[color=red][/color] and that of the Preuss School, coming up with innovations in education. But there’s an informality and unpretentiousness about San Diego. People will welcome you to these various boards, and you can have an impact almost immediately. And the climate is not bad, but basically it’s the people.”
http://www.utsandiego.com/news/2013/feb/04/san-diego-biotech-advantage-outweighs/
Sanford Burnham Medical Research Institute
http://www.sanfordburnham.org/Pages/Splash.aspx
Sanford-Burnham gets record $275M gift
Institute to use anonymous donation for research on cancer, diabetes, Alzheimer's, other diseases
http://www.utsandiego.com/news/2014/jan/28/cancer-philanthropy-stemcells/
------------------------------------------------
Thoughts on possible funding for added trials for MANF or LYMPRO?
The Sanford-Burnham Medical Research Institute has received the largest-ever single donation to a local organization, a $275 million gift aimed at helping the La Jolla-based center speed up development of drugs and therapies to treat afflictions such as cancer, diabetes and Alzheimer’s disease. ...
The latest record-setting donation was made public by Sanford-Burnham president Kristiina Vuori, who said, “The (National Institutes of Health) has been funding very basic discoveries, scientists have published papers and knowledge, (but) sometimes nothing happened. Our goal is to take those discoveries and turn them into new diagnostics and new treatments.”
The federal government, various hospitals such as the UC San Diego Health System, pharmaceutical conglomerates and biomedical institutes including Sanford-Burnham have been placing more emphasis on translational medicine in the past decade or so. ...
DH
Dr. Rubinfeld has not done anything to advance Generex/ Antigen Express. The partnership work was/is being done on Antigen Express' AE37. Great product but moving slower than a snail's pace. I'm not sure if there still is a partnership.
Generex (GNBT) some years back kicked out the CEO Anna Gluskin and the Lawyer, Mark Flecher, was put in charge (a position he did not want). No communication with shareholders and they have yet to make any recent milestones (last 4 years), IMO.
AE37 has potential but IMO, not with this management team. Those that have stock for many years (myself included) are in a wait and see if anything can be done with AE37. They continue to issue warrants to survive.
There is great info on AE37 at DigitalTradz.com. Yahoo constantly bashes the members but it is expected from yahoo posters.
I'll leave it to others to comment on Oral-lyn (Ph3 back to Ph1), Oral Recosulin (Oraly-lyn India).
All my own opinion.
DH
You are correct...
Point is AMBS retains the option for license of the I.P. for the discovery that MANF can be possibly used as a diagnostic Biomarker for T1D ...
Many opportunities with MANF ...
DH
I don't believe the partnership is still in play with Generex. There are no updates to continue operations with either AMBS or GNBT Form 10K for the previous partnership re: this particular 25K grant. GNBT had put Oral-lyn on the back burner since they are redoing their clinical trials after delivery modifications. Only Oray-lyn in India may provide some results in the near term.
AMBS may still have many agreements/funding in play with GNBT but cannot find sources.
http://diabetes.diabetesjournals.org/content/61/4/780.full#corresp-1.
Novel Neurotrophic Factors for the Treatment of
Neurodegenerative Diseases
Mart Saarma
Institute of Biotechnology, University of Helsinki & Hermo Pharma Ltd.
www.lsb2012.com/uploads//12.%201330-5%20Mart%20Saarma.pdf
Mart Saarma
Academy Professor
Institute of Biotechnology
P.O. Box 56 (Viikinkaari 9)
FI-00014 University of Helsinki, Finland
http://www.biocenter.helsinki.fi/bi/saarma/
http://www.biocenter.helsinki.fi/bi/saarma/CDNF_MANF.htm
Biology of CDNF/MANF protein family
CDNF and MANF form a novel, evolutionary conserved protein family with neurotrophic activities (1). CDNF was originally identified and characterized by our group (2, 3) and is homologous to mammalian MANF protein (4). CDNF-MANF homologue gene is also found in invertebrate animals, such as D. melanogaster and C. elegans, in which no other neurotrophic factors have been identified so far. In cells, CDNF/MANF proteins are located in the ER and are also secreted.
Parkinson’s disease (PD) is a progressive neurodegenerative disorder in which midbrain dopaminergic neurons are affected. In collaboration with Prof. Raimo Tuominen’s and Prof. Barry Hoffer’s groups we have shown that striatal delivery of CDNF protects midbrain dopaminergic neurons and restores their function in a rat 6-OHDA model (2, 5) and in a mouse MPTP model (6) of PD in vivo. Similarly with CDNF, also MANF shows protective effects on dopaminergic neurons in a rat 6-OHDA model of PD (7). In collaboration with Tapio Heino’s group we have shown that Drosophila MANF is needed for the maintenance of dopaminergic neurites and dopamine levels in the fly and is a functional ortholog of human MANF and CDNF (8). Based on our studies CDNF is a promising candidate for the treatment of PD. In collaboration with HermoPharma Ltd our aim is to take CDNF to human clinical trials on PD patients.
The mechanism of action and binding partners of CDNF and MANF are still unknown. We have resolved the crystal and NMR solution structure of human MANF and CDNF (9, 10, Hellman et al. unpublished) and a partial crystal structure of human CDNF (9). The structure of CDNF/MANF proteins consists of two domains, an amino-terminal saposin-like domain and a C-terminal SAP-domain that are connected by a flexible linker. We have recently shown that intracellular MANF, presumably via the SAP-domain, can protect SCG neurons against Bax-mediated apoptotic cell death (10). MANF is located in the ER and is able protect cells against ER stress (11). We are currently studying the cytoprotective and neuroprotective properties of MANF and CDNF by cell and molecular biology methods.
To understand the biological roles for the novel neurotrophic factors CDNF and MANF, we have created both conventional and conditional gene knockout mice. Preliminary results show interesting findings in the nervous system (Lindahl et al., unpublished).
I edited down the following for just the study names. See the link for the full info if you desire.
(2010) Novel CDNF/MANF family of neurotrophic factors, Dev Neurobiol.
Neurotrophic factor protein and uses thereof.
- (2007) Novel neurotrophic factor CDNF protects and rescues midbrain dopaminergic neurons in vivo.
- (2003) MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons.
- (2011) Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease.
- (2011) CDNF protects the nigrostriatal dopamine system and promotes recovery after MPTP treatment in mice.
- (2009) Neurotrophic factor MANF is neurorestorative in rat model of Parkinson’s disease.
- (2009) Evidence that DmMANF is an invertebrate neurotrophic factor supporting dopaminergic neurons.
- (2009) The structure of the conserved neurotrophic factors MANF and CDNF explains why they are bifunctional.
- (2011) Neurotrophic factor MANF has a unique mechanism to rescue apoptotic neurons.
- a UPR-upregulated protein, inhibits cell proliferation and ER stress-induced cell death.
DH
DNDN can ony be used on 25% of the BC patients and at the late stages of BC. Antegin Express is targetting the the other 75% first so it can fast tract through Phase III, as there is no alternative (IMO). We're looking at 6 months of trials instead of two years. Of course the finalizing, FDA reviews, and such add on at least another year for final approval. Big Pharma (BP) will already be at the door way before the FDA finalizes their approval.
Once AE get approval or BP partnership (royalties), then they will also be able to target the 25% of BC patients DNDN is targeting. Here's the kicker - DNDN is used only as a last resort adding only a few addtional months, whereas, AE treatment can be used at the earliest stages. Plus, preventative for those ladies that it is genetically passed on.
This same treatment is currently in Phase I prostate cancer. ?Check out the AE WEB site.
DH
Here is the trail info at MD Anderson Cancer Center:
http://utm-ext01a.mdacc.tmc.edu/dept/prot/clinicaltrialswp.nsf/Index/2007-0125
And the full trial listing all the sites:
http://clinicaltrials.gov/ct2/show/NCT00524277
It getting very close folks.
DH
Suppose to be on Bloomberg West
http://www.bloomberg.com/tv/schedule/
1800 ET Bloomberg West
At Bloomberg West today re: Innovator :
http://i879.photobucket.com/albums/ab357/tc2000chartreader/72389a92.mp4
(Thanks tc200chartreader on DigitalTradz)
For those that are new to Generex/Antegin Express, Elizabeth Mittendorf is the Lead Physician for the AE37 clinical trial at MD Anderson Cancer Center.
http://utm-ext01a.mdacc.tmc.edu/dept/prot/clinicaltrialswp.nsf/Index/2007-0125
This is for real folks.